Abstract
This study describes molecular interactions between human brain acetylcholinesterase (AChE) and the well known anti-neoplastic drug, methotrexate (MTX) and its comparison to ‘AChE-cyclophosphamide (CP) interactions’ that we reported previously. Docking between MTX and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of MTX within the ‘acyl pocket’ as well as ‘catalytic site’ of AChE to permit docking. However, docking of CP to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of MTX. Scope still remains in the determination of the three-dimensional structure of AChE-MTX complex by X-ray crystallography to validate the described data. The current computational study supports our previous experimental study which concluded a mixed inhibition model for AChE-inhibition by MTX. Furthermore, the present report confirms that MTX is a more efficient inhibitor of human brain AChE compared to CP with reference to Ki and ΔG values.
Keywords: Methotrexate, Docking, Enzyme-Inhibition, Human Brain Acetylcholinestrase, MTX, CTX-M-15, Cephalosporin, Cefotaxime, AChE, Desolvation, Cyclophosphamide, Galantamine
CNS & Neurological Disorders - Drug Targets
Title:Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study
Volume: 11 Issue: 2
Author(s): Shazi Shakil, Mohammad A. Kamal, Shams Tabrez, Adel M. Abuzenadah, Adeel G.A. Chaudhary, Ghazi A. Damanhouri
Affiliation:
Keywords: Methotrexate, Docking, Enzyme-Inhibition, Human Brain Acetylcholinestrase, MTX, CTX-M-15, Cephalosporin, Cefotaxime, AChE, Desolvation, Cyclophosphamide, Galantamine
Abstract: This study describes molecular interactions between human brain acetylcholinesterase (AChE) and the well known anti-neoplastic drug, methotrexate (MTX) and its comparison to ‘AChE-cyclophosphamide (CP) interactions’ that we reported previously. Docking between MTX and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of MTX within the ‘acyl pocket’ as well as ‘catalytic site’ of AChE to permit docking. However, docking of CP to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of MTX. Scope still remains in the determination of the three-dimensional structure of AChE-MTX complex by X-ray crystallography to validate the described data. The current computational study supports our previous experimental study which concluded a mixed inhibition model for AChE-inhibition by MTX. Furthermore, the present report confirms that MTX is a more efficient inhibitor of human brain AChE compared to CP with reference to Ki and ΔG values.
Export Options
About this article
Cite this article as:
Shazi Shakil, Mohammad A. Kamal, Shams Tabrez, Adel M. Abuzenadah, Adeel G.A. Chaudhary, Ghazi A. Damanhouri , Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study, CNS & Neurological Disorders - Drug Targets 2012; 11 (2) . https://dx.doi.org/10.2174/187152712800269669
DOI https://dx.doi.org/10.2174/187152712800269669 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Emerging Technologies, Recent Developments, and Novel Applications for Drug Metabolite Identification
Current Drug Metabolism Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders
Current Pharmaceutical Design Ajulemic Acid (CT3) A Potent Analog of the Acid Metabolites of THC
Current Pharmaceutical Design Multi-Nutrient Dietary Intervention Approach to the Management of Alzheimer’s Disease – A Mini-Review
Current Alzheimer Research Concurrent Estimation of Gabapentin and Nortriptyline Hydrochloride in their Combined Dosage Form Using OPA-β-Mercaptoethanol Derivatization by Spectrophotometric and Spectrofluorimetric Methods
Current Pharmaceutical Analysis Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease
Current Drug Metabolism Peptide Ligands for the Melanin-Concentrating Hormone (MCH) Receptor 1
Current Topics in Medicinal Chemistry Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design The Chemokine CXCL10 as a Therapeutic Target in Animal Models of Neuroinflammatory Disease
Letters in Drug Design & Discovery Is Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?
Current Pharmaceutical Design Analyzing of Molecular Networks for Human Diseases and Drug Discovery
Current Topics in Medicinal Chemistry Nanotheranostics in Evidence Based Personalized Medicine
Current Drug Targets Retracted: Effects of Vitamin K2 on Osteoporosis
Current Pharmaceutical Design Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology Commentary: Research Highlights (Neuronal Nicotinic Acetylcholine Receptors: Emerging Therapeutic Targets for Alcoholism)
CNS & Neurological Disorders - Drug Targets Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Meet the Editorial Board:
CNS & Neurological Disorders - Drug Targets “Impact of Smoking Cessation Treatment” on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study
Recent Patents on Anti-Cancer Drug Discovery